Oncoinvent AS: Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
All dose levels of Radspherin were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study. Radspherin is currently being evaluated in two ongoing Phase 1 trials for